ResMed acquires Maribo Medico, Denmark’s market leader in sleep and respiratory care
- Maribo Medico has been ResMed’s exclusive distribution partner in Denmark for more than 15 years.
- ResMed Maribo will help improve the lives for more of Denmark’s estimated 760,000 people with obstructive sleep apnea (OSA) and 400,000 suffering from
chronicobstructive pulmonary disease (COPD).
SAN DIEGO, Calif. – November 12–ResMed (NYSE
“Maribo Medico’s strong team and talented leadership, their market reputation, and their commitment to research and education for sleep and respiratory medicine have helped tens of thousands of people in Denmark who suffer from sleep-disordered breathing and chronic obstructive pulmonary disease,” said Anne Reiser, president of ResMed EMEA-APAC. “Maribo and ResMed together will accelerate growth while improving patient quality-of-life and reducing total healthcare system costs in Denmark. This combination is part of our global goal of improving 20 million lives by 2020.”
Maribo Medico employees, including Chief Executive Officer Mette Toxværd Larsen, will continue on in their current roles.
“We are very happy to join with ResMed to help even more people who suffer from sleep-disordered breathing or chronic respiratory diseases,” said Mette Toxværd, CEO of Maribo Medico. “We’ve had a strong and fruitful partnership with ResMed for more than 15 years, and now we will leverage their global strength to improve many more lives in Denmark as ResMed Maribo, building our position in respiratory care and digital,
Financial terms of the transaction were not disclosed.
About Maribo Medico
Founded in 2007 and based in Sjaelland, Denmark, Maribo Medico is Denmark’s leading value-added distributor specializing in providing quality products, compliance and education related to the diagnosis, treatment
The global team at ResMed (NYSE
For News Media
Global Corporate Communications
Senior Director, Investor Relations
+1 (858) 836-5971